Save up -80% on Cetuximab
Note: this is a drug discount program, not an insurance plan.
Price of Cetuximab
100ml of 2mg/ml vials
* price without discount in nearest pharmacy. Price may vary.
We offer free Cetuximab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your coupon in most local pharmacies to get a discount on Cetuximab. Claim your prescription drug card now!
Cetuximab volume of distribution
appeared to be independent of dose and approximated the vascular space of 2-3 L/m2.
What is Cetuximab
Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions. Cetuximab is marketed under the brand Erbitux/ by Eli Lilly and Company. In the United States, a regimen of cetuximab costs approximately $30,790 for an eight-week course.
Cetuximab mechanism of action
Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.
Dosage forms of Cetuximab
|Solution for infusion||Intravenous use||5 mg/ml|
Humans and other mammals
Indication of Cetuximab
Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.
Toxicity of Cetuximab
Interstitial lung disease (ILD) was reported in 3 of 633 (0.5%) patients with advanced colorectal cancer receiving cetuximab. Interstitial pneumonitis with non-cardiogenic pulmonary edema resulting in death was reported in one case. Two patients had pre-existing fibrotic lung disease and experienced an acute exacerbation of their disease while receiving cetuximab in combination with irinotecan. In the clinical investigational program, an additional case of interstitial pneumonitis was reported in a patient with head and neck cancer treated with cetuximab and cisplatin. The onset of symptoms occurred between the fourth and eleventh doses of treatment in all reported cases.
Disclaimer: before buying a Cetuximab on prescription, consult your health care provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.